Using low - molecular - weight ligands for targeting in integrated chemodynamic/starvation therapy and chemotherapy for prostate cancer DOI
Xiaoli Zhang, Jie He,

Yu An

и другие.

Research Square (Research Square), Год журнала: 2025, Номер unknown

Опубликована: Апрель 15, 2025

Abstract Targeted therapy enhances tumor elimination while reducing adverse effects by integrating multiple tumoricidal mechanisms. Low molecular weight (LMW) ligands, offering faster pharmacokinetics and improved permeability, present a viable alternative to antibodies. This study presents novel nanomedicine for prostate cancer therapy, leveraging mesoporous silica nanoparticles (MSN) as the nanocarrier encapsulate manganese dioxide (MnO2) doxorubicin (DOX). The resultant are further coated with polydopamine (PDA) layer covalently conjugated glucose oxidase (GOx), forming MSN@Mn@PDA-GOx/DOX hybrid system (hereafter termed SMPG/DOX NPs). LMW ligands (small molecule inhibitor DCL nanobody VHH) targeting prostate-specific membrane antigen (PSMA) were create DCL-SMPG/DOX VHH-SMPG/DOX. Mn2+-mediated Fenton-like reactions converted H2O2 into toxic hydroxyl radicals (·OH) under acidic conditions, enabling chemodynamic (CDT). GOx-generated gluconic acid disrupted nutrient supply, inducing starvation (ST). increased acidity amplified reaction, creating "ROS storm" that synergistically enhanced chemotherapy. specificity, efficacy, reduced side effects. In vitro, showed superior cell internalization cytotoxicity compared cellular rates of VHH-SMPG/DOX 34.1% 44.5%, respectively, significantly higher than free DOX uptake (10.3%). Moreover, DCL-SMPG/DOX-induced stronger In vivo studies demonstrated strong anti-tumor activity nanomedicine, underscoring its potential treatment. Further research is needed elucidate antitumor

Язык: Английский

Advancements in Colorectal Cancer Treatment: The Role of Metal-Based and Inorganic Nanoparticles in Modern Therapeutic Approaches DOI
Maryam Azarian, Marzieh Ramezani Farani, William C. Cho

и другие.

Pathology - Research and Practice, Год журнала: 2024, Номер 264, С. 155706 - 155706

Опубликована: Ноя. 6, 2024

Язык: Английский

Процитировано

8
Clofarabine-loaded aptamer-conjugated biodegradable nanoparticle successfully targeted CD117 overexpressed HL60 cells and potentially induced apoptosis DOI Creative Commons

Manisheeta Ray,

Ashique Al Hoque, Saptarshi Chatterjee

и другие.

Heliyon, Год журнала: 2025, Номер 11(4), С. e42450 - e42450

Опубликована: Фев. 1, 2025

Highlights:•Aptamer-conjugated clofarabine-loaded nanoparticles successfully targeted CD117 on HL60 cells suspended in medium.•Aptamer-conjugated nanoformulation sustained drug release that could maintain prolonged therapeutic levels.•The formulation potentially reduced mitochondrial membrane potential and induced apoptosis cells•This approach may revolutionize acute myeloid leukemia treatment, overcoming the limitations of conventional therapy.AbstractAcute Myeloid Leukemia (AML) is a rapidly progressing malignancy characterized by proliferation abnormal neutrophils, leading to severe symptoms complications. Current widely used treatment options include chemotherapy radiotherapy, which often result suffering from systemic toxicity resistance. To mitigate off-target side effects, strategy one remarkably successful options. For targeting AML cells, we have chosen single-strand DNA aptamer (Apt), specific for biomarker CD117, overexpressing cells. This study introduces explicitly novel employing aptamer-conjugated PLGA (Apt-CNP) receptor Clofarabine, potent nucleoside analogue, disrupts synthesis induces cancer cell death but limited its Encapsulation enables release, maintaining concentrations reducing Our findings demonstrate Apt-CNP effectively targets thereby improving delivery adverse effects healthy open new avenue more mobile floated blood including (HL60 leukemia) overcome traditional treatments.Graphical abstract

Язык: Английский

Процитировано

0
Biological roles and clinical applications of EpCAM in HCC DOI Creative Commons
Peng Liu, Qun Zhang, Fengchao Liu

и другие.

Discover Oncology, Год журнала: 2025, Номер 16(1)

Опубликована: Март 14, 2025

Epithelial cell adhesion molecule (EpCAM) is an important biomarker in tumors. In hepatocellular carcinoma (HCC), EpCAM + cells exhibit high invasiveness, tumorigenic ability, therapeutic resistance, and self-renewal often identified as liver cancer stem (CSCs). Detecting tumor lesions circulation valuable for predicting patient prognosis monitoring outcomes, emphasizing its clinical significance. Given broad expression HCC, especially CSCs circulating (CTCs), EpCAM-targeting agents have garnered substantial research interest. However, the role of HCC progression regulatory mechanisms remains poorly understood. Furthermore, applications EpCAM, such liquid biopsy targeted therapies, are still controversial. This review summarizes biological properties cells, explores governing expression, discusses significance using a prognostic marker target.

Язык: Английский

Процитировано

0
Nanoparticle-Based Delivery Systems for Phytochemicals in Cancer Therapy: Molecular Mechanisms, Clinical Evidence, and Emerging Trends DOI
Mahmoud A.H. Mostafa, Hani M. J. Khojah

Drug Development and Industrial Pharmacy, Год журнала: 2025, Номер unknown, С. 1 - 31

Опубликована: Март 21, 2025

This review examines recent advancements in nanoparticle-based delivery systems for phytochemicals, focusing on their role overcoming multidrug resistance, improving therapeutic efficacy, and facilitating clinical translation. highlights advances nanoparticle-enabled phytochemical to enhance bioavailability, improve outcomes, enable targeted applications. By comparing various nanoparticle systems, formulation methods, efficacy data, it identifies gaps current research guides the development of more effective, next-generation phytochemical-loaded nanocarriers. A systematic literature published between 2000 2024 was conducted using PubMed, Scopus, Web Science. Articles cancer therapy were included. Compounds such as curcumin, resveratrol, quercetin, epigallocatechin gallate demonstrate enhanced anti-cancer when encapsulated nanoparticles, leading improved increased tumor cell targeting, reduced toxicity. Clinical trials indicate regression fewer adverse effects. Emerging approaches-such nanogels, hybrid combination therapies with immune checkpoint inhibitors-further refine treatment efficacy. Nanoparticle-based significantly potential making them promising candidates safer, effective treatments. However, challenges related regulatory guidelines, scalability, long-term safety must be addressed fully realize potential.

Язык: Английский

Процитировано

0
Using low - molecular - weight ligands for targeting in integrated chemodynamic/starvation therapy and chemotherapy for prostate cancer DOI
Xiaoli Zhang, Jie He,

Yu An

и другие.

Research Square (Research Square), Год журнала: 2025, Номер unknown

Опубликована: Апрель 15, 2025

Abstract Targeted therapy enhances tumor elimination while reducing adverse effects by integrating multiple tumoricidal mechanisms. Low molecular weight (LMW) ligands, offering faster pharmacokinetics and improved permeability, present a viable alternative to antibodies. This study presents novel nanomedicine for prostate cancer therapy, leveraging mesoporous silica nanoparticles (MSN) as the nanocarrier encapsulate manganese dioxide (MnO2) doxorubicin (DOX). The resultant are further coated with polydopamine (PDA) layer covalently conjugated glucose oxidase (GOx), forming MSN@Mn@PDA-GOx/DOX hybrid system (hereafter termed SMPG/DOX NPs). LMW ligands (small molecule inhibitor DCL nanobody VHH) targeting prostate-specific membrane antigen (PSMA) were create DCL-SMPG/DOX VHH-SMPG/DOX. Mn2+-mediated Fenton-like reactions converted H2O2 into toxic hydroxyl radicals (·OH) under acidic conditions, enabling chemodynamic (CDT). GOx-generated gluconic acid disrupted nutrient supply, inducing starvation (ST). increased acidity amplified reaction, creating "ROS storm" that synergistically enhanced chemotherapy. specificity, efficacy, reduced side effects. In vitro, showed superior cell internalization cytotoxicity compared cellular rates of VHH-SMPG/DOX 34.1% 44.5%, respectively, significantly higher than free DOX uptake (10.3%). Moreover, DCL-SMPG/DOX-induced stronger In vivo studies demonstrated strong anti-tumor activity nanomedicine, underscoring its potential treatment. Further research is needed elucidate antitumor

Язык: Английский

Процитировано

0